Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

NCT04585958 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

55

Enrollment

NIH

Sponsor class

Conditions

Metastatic Malignant Solid Neoplasm
Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
Unresectable Malignant Solid Neoplasm

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
DRUG: Olaparib
BIOLOGICAL: Trastuzumab Deruxtecan

Sponsor

National Cancer Institute (NCI)